Randomized Phase Ii Study of Thalidomide for the Control of Delayed Chemotherapy-Induced Nausea and Vomiting
L. Yun-Peng,Z. Jingdong,T. Yuee,J. Bo,Y. Ping,Z. Mingfang,S. Jing,Z. Lingyun,L. Zhi
DOI: https://doi.org/10.1200/jco.2008.26.15_suppl.9614
IF: 45.3
2008-01-01
Journal of Clinical Oncology
Abstract:9614 Background: The aim of the study is to evaluate the efficacy of thalidomide for treatment of delayed chemotherapy-induced nausea and vomiting (CINV) with emetogenic chemotherapy. Methods: Chemotherapy-naive patients with histological confirmed malignancies were randomized divided into 2 groups: A-B group (A, ramosetron 0.3mg IV plus dexamethasone 10mg IV or PO on day 1, was given in the first cycle and B, ramosetron plus dexamethasone on day1 plus thalidomide 150 mg orally twice a day on day 1 through 5, in the second cycle) and B-A group (those drugs were given in the reverse sequence). The primary end point was the efficacy of thalidomide in controlling delayed CINV. The secondary end point was the safety of thalidomide. The descriptive statistics was used. Fertile patients must use effective contraception. Results: Of 43 patients enrolled between October, 2006 to January, 2007, 41 patients (95%) were assessable. Median age was 53 years (range 43–69). Chemotherapy regimen included CDDP-based regimen(CDDP≥70 mg/m2, d1), CEF(cyclophosphamide 600mg/m2, d1, epirubicin 60–80mg/m2, d1, plus 5-fluorouracil 600mg/m2, d1, Q 3 W),CE(cyclophosphamide 600mg/m2, d1, epirubicin 60–80mg/m2, d1, Q 3 W) and mFOFOX6 (oxaliplatin 100–130mg/m2, IV, over 2 hours, d1, leucovorin 200mg/m2, IV, over 2 hours, d1, followed by 46-hour 2,800mg/m2 5-fluorouracil,IV, Q 3 W). Pt characteristics (%) were: male/female 41.5/58.5; ECOG PS 0/1 51.2/48.8; lung cancer/gastrointestinal cancer/breast cancer/other 14.6/70.7/9.8/4.9; CDDP-based regimen/CEF/CE/mFOFOX6 19.5/7.3/2.4/70.7, Group A-B/ B- A 53.7/46.3. Complete response of delayed nausea and emesison on day 2 through 5 were 48.7% of group B vs 17.1% of group A (p=0.002) and 78.0% of group B vs 56.1% of group A (p=0.034), respectively. Adverse effects were mostly mild to moderate, and no grade 4 toxicities in any treatment cycle. Sedation were more common in group B (31.7% vs 0%, p=0.000 on day 1; 36.59% vs 4.88%, p=0.000 on day 2; 29.27% vs 2.44%, p=0.001 on day 3; 24.39% vs 2.44%, p=0.004 on day 4). While disappetite were more common in group A (68.29% vs 36.59%, p=0.004 on day 3; 63.41% vs 41.46%, p=0.047 on day 4). Conclusions: This is the first report to demonstrate that thalidomide is safe and effective in controlling delayed CINV. No significant financial relationships to disclose.